Search
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalThe compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313]. … Created by Altimmune, Inc., NasoVAX is currently being developed for seasonal and pandemic use as it can activate humoral and cellular immune responses.
GI-5005
go.drugbank.com/drugs/DB05942InvestigationalGI-5005 is whole, heat-killed recombinant yeast genetically modified to express HCV-specific protein targets. … Tarmogens are believed to activate both an innate immune response via Toll-like receptors (TLRs), as well as an adaptive, antigen specific cellular immune response.
Tenofovir
go.drugbank.com/drugs/DB14126Investigational[A37693] In the most strict sense and due to the fact that it presents a phosphate group bound to the nitrogenous base, it is determined as an actual nucleotide analog. … A37693] The antiviral activities of tenofovir were first reported in 1993 and this agent was commercially available since 2008 in the form of [tenofovir disoproxil] and [tenofovir alafenamide] in order to
BI 4060107
go.drugbank.com/drugs/DB33963ExperimentalBI 4060107 is under investigation in clinical trial NCT07827144 (A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours)).
Fluciclatide
go.drugbank.com/drugs/DB14842InvestigationalThe conditions targeted by [18F]Fluciclatide in these studies include high-grade glioma, lung cancer, and kidney neoplasms … Fluciclatide, an investigational radiotracer intended for PET imaging, was under investigation in clinical trials NCT00565721 and NCT01961583 to evaluate its ability to detect tumors and angiogenesis.
PIKA rabies vaccine
go.drugbank.com/drugs/DB17963InvestigationalPIKA rabies vaccine is a novel vaccine developed by YS Biopharma.
2G7
go.drugbank.com/drugs/DB18589Experimental2G7 is an anti-TGF-beta monoclonal antibody developed by Genentech.
Bisegliptin
go.drugbank.com/drugs/DB06127InvestigationalIt is an orally active, dipeptidyl peptidase-IV (DPPIV) inhibitor which lowers blood glucose levels by blocking the degradation of the hormone GLP-1 thereby stimulating glucose-dependent insulin secretion
Ceftobiprole medocaril
go.drugbank.com/drugs/DB14733ApprovedMedicinal Products for Human Use (CHMP) adopted a negative opinion of ceftobiprole medocaril in February 2010, recommending the refusal of its marketing authorization in the European Union primarily due to
Flavoxate
go.drugbank.com/drugs/DB01148ApprovedIts therapeutic usefulness and its mechanism of action are not clear. … It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist. [PubChem]